Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGF...
Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer
About this item
Full title
Author / Creator
Publisher
Dove Medical Press Limited
Journal title
Language
English
Formats
Publication information
Publisher
Dove Medical Press Limited
Subjects
More information
Scope and Contents
Contents
Background: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor, exerts remarkable effects against EGFR T790M resistance mutation-positive non-small cell lung cancer. Identifying T790M mutation by re-biopsy is essential before prescribing osimertinib. Tissue biopsy is the golden standard for this purpose, but...
Alternative Titles
Full title
Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A583694771
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A583694771
Other Identifiers
ISSN
1178-6930
E-ISSN
1178-6930
DOI
10.2147/OTT.SI61745
